Related Experiment Video
Updated: Jul 17, 2025

11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
TP53 status and impact on AML prognosis within the ELN 2022 risk classification
Shaun Fleming1,2, Xavier Cheng-Hong Tsai3, Rhiannon Morris4
1Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.
Blood
|August 30, 2023
Abstract:
This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of -7, -5/del(5q), -17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.

